Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
This is the last part of my discussion with Dr. Matthew Horton, a pathologist with a special training and a great expertise in lung pathology who works here in Seattle at a company called CellNetix.
We focus in this last one on the increasing focus on molecular markers in making clinical decisions and how this is changing the relationship of pathologists with oncologists, as well as the need for pathologists to provide this information in a timely way.
dr-horton-pt-3-transition-to-molecular-pathology-audio-podcast
dr-horton-pt-3-transition-to-molecular-pathology-transcript
dr-horton-pt-3-transition-to-molecular-pathology-figures
Next, we'll turn to coverage of imaging issues in cancer management.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.